公开(公告)号：US20230346872A1

公开(公告)日：2023-11-02

申请号：US17922977

申请日：2021-05-06

Applicant: Academia Sinica

Inventor： Che MA ,  Jia-Tsrong JAN

IPC: A61K36/896 ,  A61K45/06 ,  A61P31/14

CPC classification number: A61K36/896 ,  A61K45/06 ,  A61P31/14

Abstract: Disclosed herein is a method for treating or preventing a coronavirus infection, which comprises administering to a subject in need thereof an effective amount of a composition comprising Flt3 receptor interacting lectin (FRIL) from Lablab purpureus. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, a Lablab purpureus FRIL, and an additional therapeutic agent.

公开(公告)号：US20210386820A1

公开(公告)日：2021-12-16

申请号：US17274122

申请日：2019-09-06

Applicant: ACADEMIA SINICA

Inventor： Che MA ,  Yu-Min LIU ,  Jia-Tsrong JAN

IPC: A61K38/17 ,  A61P31/16

Abstract: The present invention relates to antiviral lectin and uses thereof. Particularly, the present invention relates to a complex-type (CX-type) and/or hybrid-type (HY-type) glycan binding lectin for use in treating or preventing influenza virus infection. The present invention also provides a method for treating or preventing influenza virus infection by administrating to a subject in need said lectin or a composition comprising the same.